New review suggests regular coffee consumption reduces the risk of developing type 2 diabetes by approx. 30%
A new review paper has analysed scientific studies, covering nearly 1.2 million participants in total, to gain a better understanding of how coffee consumption affects the development of type 2 diabetes and its associated complications.
‘Coffee consumption and reduced risk of developing type 2 diabetes: a systematic review with meta-analysis’1, by Associate Professors Mattias Carlström and Susanna Larsson2, found that aggregated evidence from 30 studies indicates that coffee consumption reduces the risk of developing type 2 diabetes by approximately 30%.
The review found that both caffeinated and decaffeinated coffee consumption reduced the risk of type 2 diabetes. The association was dose-dependent: the risk of type 2 diabetes decreased, respectively, by 7% (caffeinated) and 6% (decaffeinated) per cup per day. However, the risk reduction of new-onset type 2 diabetes appeared to be slightly stronger with caffeinated coffee.
The pooled relative risk for incident type 2 diabetes was 0.71 for the highest category of coffee consumption (median consumption, 5 cups per day) compared to the lowest category (median consumption, 0 cups per day).
The relationship between coffee consumption and type 2 diabetes is of significant interest, given the increasing worldwide prevalence of the disease. Type 2 diabetes is also associated with a number of adverse complications, further increasing the burden on both the individual and the healthcare system.
The authors reviewed the potential underlying mechanisms contributing to coffee consumption’s effect on type 2 diabetes risk. These potential mechanisms include coffee’s antioxidant properties, as oxidative stress has been linked to a number of adverse effects on cardiovascular, metabolic and renal functions. It has been demonstrated that acute as well as long-term intake of coffee can lower oxidative stress associated with type 2 diabetes. A number of studies have also shown that regular coffee consumption may reduce levels of pro-inflammatory markers: chronic low-grade inflammation has been linked to cardiovascular and metabolic disorders, such as type 2 diabetes.
The paper’s authors note that long-term randomised placebo-controlled trials are needed to confirm the observed protective association between coffee consumption and types 2 diabetes risk, and to help understand the underlying mechanisms of this relationship. As an individual’s genotype changes the way they metabolise caffeine, interventional studies should categorise participants accordingly.
Although future studies are still needed, the existing knowledge from epidemiological studies emphasises the prevention of type 2 diabetes with increasing intake of coffee.
The authors conclude that coffee – alongside important lifestyle changes to address a range of risk factors – could offer new therapeutic opportunities for type 2 diabetes and associated complications.
